Bobby Corwin, Daughterless Sobbing

@bobbycorwin.bsky.social

He/Him | yells at engineers (aerospace), LA CA

GOOD NEWS! Phase I clinical trial results out of Johns Hopkins show a first-of-its-kind vaccine designed to target common KRAS mutations was safe AND stimulated KRAS-specific T-cell responses in 90% of study participants who were at HIGH risk of developing pancreatic ductal adenocarcinoma (PDAC).

Pancreatic Cancer Vaccine Triggers Immune Response Before Tumors Develop

Phase I results show early promise for a vaccine designed to prevent pancreatic cancer in people at high risk of developing the disease.

insideprecisionmedicine.com